rna
virus
capabl
rapid
spread
sever
potenti
lethal
diseas
anim
human
develop
revers
genet
system
manipul
studi
rna
viru
genom
provid
platform
design
optim
viral
mutant
vaccin
develop
review
impact
rna
viru
revers
genet
system
past
current
effort
design
effect
safe
viral
therapeut
vaccin
vaccin
remain
one
greatest
accomplish
human
ingenu
scientif
endeavor
combin
global
effort
public
health
commun
rate
incid
mortal
associ
infect
rna
virus
polio
measl
mump
rubella
declin
greater
compar
prevaccin
rate
though
highli
success
past
convent
approach
rna
viru
vaccin
develop
liveattenu
passag
forward
genet
inactiv
may
less
effici
gener
good
candid
ration
target
mutagenesi
revers
genet
advanc
recombin
dna
technolog
viru
revers
genet
provid
key
critic
insight
replic
pathogenesi
rna
virus
facilit
vaccin
develop
target
modif
direct
attenu
advent
revers
genet
molecular
engin
virus
transform
field
open
access
virolog
permit
studi
target
genet
chang
viru
genom
first
infecti
rna
viru
clone
isol
cdna
gener
polioviru
sinc
revers
genet
technolog
recombin
viru
design
employ
gener
revers
genet
clone
repres
major
viru
famili
addit
techniqu
approach
becom
focu
new
effort
design
vaccin
incorpor
specif
chang
either
componentbas
virusbas
system
induc
last
immun
host
without
health
risk
deleteri
effect
sinc
develop
effect
liveattenu
vaccin
new
vaccin
prepar
util
wellestablish
vector
express
specif
viral
protein
compon
subunit
vaccin
develop
viruslik
particl
vlp
continu
shape
domain
vaccin
discoveri
develop
challeng
establish
safe
immunogen
platform
induc
last
immun
context
wide
varieti
viral
system
result
remark
creativ
variabl
approach
employ
use
replic
virus
vaccin
liveattenu
chimer
vectorbas
platform
benefit
high
immunogen
lower
cost
eas
transport
administ
yet
virus
potenti
revert
pathogen
phenotyp
may
underattenu
immunocompromis
host
convers
compon
subunit
kill
pathogen
vaccin
benefit
gener
safer
use
display
immunogen
antigen
howev
cost
time
develop
weaker
induc
immun
respons
present
challeng
design
implement
review
describ
rna
viru
revers
genet
system
provid
overview
current
effort
use
revers
genet
technolog
develop
safe
effect
vaccin
current
rna
viru
revers
genet
system
make
use
multipl
common
featur
rna
viru
biolog
first
rna
virus
gener
genom
copi
activ
viral
rnadepend
rna
polymeras
rdrp
addit
nearli
rna
viru
replic
strategi
independ
host
cell
nucleu
instead
resid
cytoplasm
positivestrand
rna
virus
polioviru
immedi
entri
uncoat
genom
rna
directli
translat
host
ribosom
gener
viral
protein
product
sinc
viru
rare
need
packag
addit
nonstructur
protein
virion
positivesens
rna
viru
revers
genet
system
larg
focu
deliveri
either
transcrib
genom
rna
cell
cytoplasm
deliveri
cdna
control
viral
transcript
promot
cmv
figur
howev
negativestrand
doublestrand
rna
viru
revers
genet
system
often
requir
use
addit
helper
construct
introduc
rdrp
essenti
protein
initi
genom
replic
recent
altern
approach
employ
field
influenza
research
synthes
viral
rna
drive
mrna
product
activ
host
polymeras
pol
pol
ii
approach
simplifi
logist
plasmid
transfect
increas
efficaci
recombin
viru
recoveri
similar
approach
success
employ
recoveri
arenaviru
lymphocyt
choriomenig
viru
lcmv
one
addit
platform
employ
rna
viru
infecti
clone
gener
bacteri
artifici
chromosom
bac
bac
construct
singlecopi
dna
plasmid
base
fplasmid
bacteria
genet
stabl
e
coli
permit
insert
larg
dna
fragment
transcrib
control
transcript
promot
bac
construct
employ
mani
year
recoveri
larg
dna
virus
howev
genet
stabil
construct
led
use
recombin
rna
viru
platform
sever
positivestrand
rna
virus
one
negativestrand
rna
viru
use
bac
platform
revers
genet
design
tabl
sinc
rna
viru
replic
strategi
segreg
host
genom
replic
machineri
rna
virus
modifi
host
gene
express
caus
oncogenesi
result
rna
revers
genet
system
typic
account
potenti
transform
host
cell
lastli
rna
virus
limit
small
genom
size
major
smaller
kb
due
reduc
genom
stabil
lower
fidel
viral
rdrp
subsequ
revers
genet
approach
often
employ
use
cdna
genet
clone
greater
versatil
manipul
modif
viru
genom
rdrp
polymeras
negativestrand
rna
viru
revers
genet
platform
often
involv
transfect
electropor
genom
commonli
subgenom
cdna
permiss
cell
combin
either
helper
viru
helper
plasmid
driven
rdrp
negativestrand
rna
system
employ
host
polymeras
pol
ii
pol
ii
promot
drive
viral
rna
synthesi
mrna
product
positiveand
negativestrand
revers
genet
system
rdrp
typic
constitut
transient
express
permiss
cell
type
positivestrand
rna
virus
genom
infecti
upon
entri
host
cell
upon
entri
host
ribosom
translat
viral
rna
one
polyprotein
requir
either
host
viral
proteas
process
although
mani
differ
revers
genet
platform
use
gener
positivestrand
rna
viru
clone
nearli
share
common
goal
introduc
either
sens
genom
rna
transcript
directli
cdna
transcrib
includ
rdrp
figur
describ
approach
employ
gener
infecti
clone
picornavirus
coronavirus
flavivirus
strategi
current
appli
develop
vaccin
picornavirus
famili
nonenvelop
positivestrand
rna
virus
collect
infect
wide
rang
human
anim
host
human
picornavir
pathogen
caus
ill
vari
common
cold
poliomyel
picornaviru
virion
consist
icosahedr
capsid
structur
surround
rna
genom
rang
approxim
kb
size
polioviru
rhinoviru
remain
two
extens
studi
picornavirus
date
becom
model
system
studi
rna
viru
biolog
pathogenesi
epidemiolog
extens
effort
began
develop
implement
polio
vaccin
hope
erad
viru
sinc
nonhuman
primat
reservoir
known
exist
natur
effect
inactiv
salk
vaccin
liveattenu
sabin
vaccin
led
increas
effort
develop
design
vaccin
mani
human
pathogen
intern
vaccin
effort
aim
erad
diseas
success
employ
strategi
implement
vaccin
polioviru
open
door
evalu
new
approach
effort
studi
understand
rna
viru
biolog
major
step
occur
racaniello
baltimor
introduc
fulllength
cdna
clone
polioviru
cell
recov
infecti
viru
although
initi
mechan
cdna
clone
plasmid
could
give
rise
product
rna
viru
infect
unknown
cdna
platform
approach
use
racaniello
advanc
understand
engin
plasmid
gene
deliveri
led
effici
cdnabas
system
repres
primari
revers
genet
approach
use
recoveri
picornavirus
today
commerci
avail
rhinoviru
vaccin
exist
today
despit
effect
revers
genet
platform
sever
serotyp
rhinovirus
remain
primari
caus
common
cold
worldwid
extens
studi
year
yet
great
puzzl
develop
broadli
protect
rhinoviru
vaccin
involv
solv
overwhelm
task
develop
immunogen
platform
provid
protect
immun
greater
serotyp
rhinoviru
current
circul
natur
capsid
rhinoviru
compris
four
distinct
serotypespecif
protein
known
immunogen
potenti
elicit
crossreact
antibodi
yet
develop
broadlyneutr
rhinoviru
protect
like
requir
formul
polyval
vaccin
includ
incorpor
sever
serotyp
variant
immunogen
capsid
protein
effort
design
polyval
rhinoviru
vaccin
formul
yet
provid
broad
immunogen
memori
necessari
effect
howev
region
precursor
shown
conserv
across
b
group
rhinovirus
combin
h
promot
adjuv
induc
crossserotyp
immun
respons
mice
discoveri
conserv
epitop
recent
develop
chimer
new
revers
genet
platform
includ
mous
model
infect
may
provid
novel
avenu
effici
display
epitop
breadth
rhinoviru
divers
coronavirus
envelop
positivestrand
rna
virus
encod
largest
known
rna
viru
genom
vari
size
kb
coronaviru
infect
human
associ
upper
lower
respiratori
ill
rang
sever
common
cold
sever
acut
respiratori
syndrom
sar
last
year
four
new
human
coronavirus
identifi
includ
sar
coronaviru
recent
middl
east
respiratori
syndrom
mer
coronaviru
despit
high
clinic
econom
burden
potenti
emerg
infecti
diseas
commerci
avail
vaccin
current
exist
current
two
common
platform
use
gener
fulllength
infecti
coronaviru
clone
first
platform
involv
vitro
transcript
cap
fulllength
cdna
clone
coronaviru
genom
follow
introduct
compet
cell
either
transfect
electropor
coronaviru
genom
approxim
kb
size
often
maintain
fragment
lowcopi
plasmid
viru
assembl
fragment
restrict
digest
ligat
togeth
prior
transcript
approach
success
use
recov
clone
mani
coronavirus
includ
transmiss
gastroenter
viru
tgev
murin
hepat
viru
mhv
sar
coronaviru
sarslik
bat
coronavirus
mer
coronaviru
anoth
common
platform
util
exist
bac
technolog
coronaviru
genom
introduc
bac
construct
control
cmv
promot
approach
success
use
recov
clone
human
virus
mer
coronaviru
approach
yield
product
infect
high
titer
progeni
viru
third
approach
involv
vaccinia
vector
platform
also
use
success
product
human
infecti
clone
effort
design
coronaviru
vaccin
focus
varieti
approach
includ
develop
inactiv
viru
liveattenu
viru
varieti
subunit
vaccin
one
major
focu
current
coronaviru
vaccin
effort
focus
way
creat
liveattenu
vaccin
strain
combin
exist
treatment
less
virul
stabl
viru
platform
sar
epidem
patient
show
littl
improv
treat
ribavirin
recent
studi
shown
coronavirus
resist
ribavirin
treatment
due
presenc
viral
exonucleas
proofread
activ
addit
delet
exonucleas
proofread
activ
result
hypermut
phenotyp
appear
genet
stabl
induc
protect
murin
model
recent
outbreak
merscov
trigger
demand
develop
mer
vaccin
sever
approach
explor
includ
identifi
effect
neutral
antibodi
use
receptorbind
domain
spike
glycoprotein
compon
induc
immun
direct
chang
recombin
merscov
avail
effect
revers
genet
platform
coronavirus
associ
high
mortal
virus
sar
mer
coronavirus
potenti
low
cost
develop
implement
provid
promis
creat
effect
vaccin
platform
flavivirus
small
envelop
positivestrand
rna
virus
infect
wide
rang
host
flaviviru
genom
markedli
smaller
coronavirus
approxim
kb
size
transmiss
flavivirus
depend
upon
arthropod
vector
henc
common
name
arbovirus
flaviviru
diseas
rang
asymptomat
sever
neurolog
diseas
enceph
mening
myeliti
yellow
fever
viru
yfv
deadli
flaviviru
associ
death
annual
identifi
walter
reed
first
human
viral
pathogen
ever
discov
outbreak
diseas
connect
flavivirus
stress
import
develop
revers
genet
platform
efficaci
vaccin
similar
picornavirus
nearli
flaviviru
revers
genet
platform
involv
either
vitro
transcript
fulllength
ligat
cdna
fragment
genom
use
bacteri
artifici
chromosom
bac
platform
tabl
subsequ
transfect
electropor
compet
cell
revers
genet
platform
develop
wide
rang
flavivirus
includ
yfv
dengu
type
jev
kunjin
viru
tickborn
enceph
viru
tbev
murray
valley
enceph
viru
langat
viru
west
nile
viru
wnv
omsk
hemorrhag
fever
viru
advanc
recombin
flaviviru
approach
instrument
new
vaccin
design
effort
first
vaccin
effort
direct
gener
inactiv
liveattenu
strain
vaccin
flavivirus
max
theiler
develop
safe
yfv
liveattenu
vaccin
call
use
serial
passag
viru
origin
isol
african
patient
vaccin
composit
use
today
remain
larg
first
develop
year
ago
provid
protect
immun
year
jev
first
isol
studi
inactiv
vaccin
deriv
mous
brain
first
develop
japan
current
formul
jev
vaccin
includ
inactiv
strain
liveattenu
strain
elicit
greater
immunogen
broader
protect
origin
nakayama
strain
despit
success
vaccin
develop
yfv
jev
uniqu
challeng
present
develop
vaccin
wellknown
flavivirus
dengu
viru
new
emerg
flavivirus
wnv
dengu
viru
endem
tropic
subtrop
locat
worldwid
date
five
distinct
serotyp
dengu
viru
known
includ
new
serotyp
identifi
infect
one
serotyp
increas
sever
diseas
upon
secondari
infect
differ
serotyp
consequ
dengu
viru
vaccin
must
either
provid
protect
extent
serotyp
prevent
prime
increas
diseas
heterotyp
infect
remov
immunogen
compon
viru
caus
increas
diseas
sever
upon
heterotyp
infect
effort
develop
stabl
chimer
platform
develop
dengu
viru
vaccin
recent
focus
express
dengu
viru
surfac
protein
chimer
virus
stabl
flavivirus
yfv
one
vaccin
candid
tetraval
vaccin
sanofi
pasteur
involv
format
chimer
yfv
strain
viru
contain
prme
gene
dengu
serotyp
approach
also
recent
adapt
develop
similar
vaccin
candid
recent
identifi
wnv
despit
sever
commerci
avail
wnv
vaccin
veterinari
purpos
remain
approv
wnv
vaccin
human
futur
licensur
dengu
wnv
vaccin
like
continu
focu
develop
liveattenu
inactiv
viru
model
vaccin
due
high
immunogen
flaviviru
infect
negativestrand
rna
viru
genom
antigenom
act
mrna
substrat
rdrp
must
encapsid
nucleocapsid
form
ribonucleoprotein
complex
rnp
antigenom
negativestrand
rna
virus
introduc
either
linear
cdna
plasmid
promot
normal
cotransfect
one
plasmid
encod
nucleocapsid
replicas
machineri
due
biolog
requir
initi
infect
develop
negativestrand
rna
viru
revers
genet
system
slower
positivestrand
viru
system
initi
recoveri
effort
gener
infecti
clone
involv
recoveri
virus
use
helper
virus
could
suppli
viral
gene
protein
necessari
replic
howev
approach
made
difficult
isol
mutant
interest
first
recoveri
negativestrand
rna
viru
complet
cdna
achiev
rabi
viru
despit
biolog
limit
challeng
work
negativestrand
rna
virus
sever
effect
negativestrand
rna
viru
vaccin
success
introduc
mani
current
vari
phase
clinic
trial
describ
approach
employ
gener
infecti
clone
vaccin
paramyxovirus
orthomyxovirus
paramyxovirus
envelop
negativesens
singlestrand
rna
virus
respons
varieti
human
anim
diseas
human
paramyxovirus
identifi
respons
diseas
includ
measl
mump
pneumonia
common
cold
paramyxovirus
carri
singl
copi
genom
typic
kb
length
like
negativestrand
rna
virus
paramyxovirus
must
incorpor
replic
machineri
includ
rdrp
virion
assembl
paramyxoviru
revers
genet
system
employ
similar
mechan
first
fulllength
genom
antigenom
helper
plasmid
express
nucleocapsid
polymeras
protein
clone
cdna
transcript
control
promot
rna
polymeras
plasmid
cotransfect
permiss
cell
line
earlier
revers
genet
system
util
coinfect
approach
vaccinia
viru
express
howev
modern
revers
genet
system
use
cell
line
transfect
plasmid
recent
first
bacbas
revers
genet
system
negativestrand
rna
viru
develop
respiratori
syncyti
viru
rsv
revers
genet
system
mani
paramyxovirus
gener
includ
measl
viru
mump
viru
hendra
viru
nipah
viru
rsv
despit
avail
revers
genet
system
develop
paramyxoviru
vaccin
met
variabl
success
first
paramyxoviru
vaccin
develop
john
ender
abl
develop
cultiv
system
measl
viru
cultur
attenu
measl
viru
call
edmonston
strain
name
child
isol
edmonston
strain
though
initi
underattenu
later
adapt
led
success
licens
measl
vaccin
mauric
hilleman
abl
build
success
liveattenu
measl
vaccin
cultur
adapt
passag
fertil
hen
egg
strain
mump
call
jeryl
lynn
name
daughter
isol
hilleman
later
instrument
develop
mmr
vaccin
combin
liveattenu
strain
measl
mump
rubella
wistar
ra
strain
first
licens
use
earli
success
measl
mump
vaccin
prompt
renew
effort
develop
vaccin
pathogen
rna
virus
one
greatest
challeng
viral
vaccin
design
remain
develop
vaccin
respiratori
syncyti
viru
rsv
respiratori
syncyti
viru
rsv
first
isol
chimpanze
display
upper
respiratori
ill
sinc
identif
rsv
becom
recogn
lead
caus
infant
mortal
viru
worldwid
unit
state
alon
rsv
upper
lower
respiratori
infect
led
hospit
annual
despit
high
clinic
burden
licens
rsv
vaccin
avail
current
treatment
cost
prohibit
provid
passiv
immun
administr
prophylact
antibodi
suscept
popul
rsv
infect
young
infant
consequ
ideal
rsv
vaccin
must
immunogen
genet
stabl
safe
vaccin
infant
howev
earli
tragic
failur
formalininactiv
rsv
vaccin
dampen
effort
develop
implement
new
vaccin
date
clinic
advanc
rsv
vaccin
candid
liveattenu
virus
develop
viru
passag
reconstitut
revers
genet
one
promis
candid
date
includ
mani
introduc
mutat
render
viru
temperaturesensit
provid
level
protect
howev
candid
abl
achiev
level
protect
genet
stabil
necessari
implement
ongo
studi
continu
evalu
new
target
attenu
howev
success
develop
rsv
vaccin
requir
find
proper
balanc
attenu
immunogen
orthomyxovirus
envelop
negativesens
rna
virus
whose
genom
consist
multipl
linear
segment
approxim
kb
size
similar
paramyxovirus
mani
orthomyxovirus
caus
respiratori
ill
human
notabl
influenza
flu
key
hallmark
orthoymyxoviru
evolut
reassort
viru
genom
coinfect
cell
order
transcript
activ
influenza
virus
requir
function
activ
viral
ribonucleoprotein
complex
rnp
consist
viral
genom
rna
nucleoprotein
np
viral
rdrp
compris
pa
protein
first
revers
genet
approach
develop
orthomyxovirus
gener
influenza
viru
iav
howev
system
util
helper
virus
select
recov
recombin
first
helper
virusfre
system
develop
around
turn
millennium
first
system
requir
cotransfect
four
plasmid
control
pol
ii
promot
well
eight
plasmid
express
eight
viral
rna
segment
number
plasmid
cotransfect
recoveri
vari
greatli
depend
upon
number
viral
genom
segment
organ
helper
protein
construct
rang
express
two
helper
protein
two
plasmid
use
pol
ii
promot
ire
mani
howev
recent
advanc
revers
genet
platform
reduc
number
total
plasmid
need
less
use
bidirect
express
system
system
human
pol
promot
coupl
either
murin
poli
termin
drive
viral
rna
synthesi
cmv
pol
ii
promot
respons
viral
mrna
synthesi
improv
product
iav
howev
gener
recombin
viru
vaccin
limit
select
number
mammalian
cell
line
african
green
monkey
kidney
epitheli
cell
vero
madin
darbi
canin
kidney
mdck
cell
howev
cell
line
limit
transfect
differ
pol
pol
ii
compat
hinder
efficaci
uniand
bidirect
approach
incorpor
speciesspecif
polymeras
promot
provid
improv
efficaci
recoveri
sever
cell
line
recent
advanc
combin
pol
driven
iav
gene
singl
plasmid
pol
ii
drive
gene
addit
plasmid
approach
improv
probabl
singl
cell
receiv
necessari
plasmid
recoveri
avail
applic
revers
genet
system
studi
identifi
structur
function
influenza
protein
revolution
influenza
vaccin
strategi
mani
year
trival
vaccin
current
provid
consist
three
separ
strain
strain
b
strain
select
base
recommend
prior
next
flu
season
howev
vaccin
made
use
either
liveattenu
coldadapt
inactiv
viru
grown
fertil
chicken
egg
next
gener
vaccin
strategi
includ
tetraval
quadrival
vaccin
may
grown
anim
cell
cultur
rather
chicken
egg
viruslik
particl
vlp
cultur
frugiperda
insect
cell
fda
approv
season
influenza
vaccin
compris
purifi
ha
protein
prepar
use
baculovirusexpress
system
recombin
vaccin
success
use
vaccin
individu
year
age
repres
major
step
influenza
vaccin
design
implement
system
reduc
product
time
compar
convent
eggbas
approach
major
frontier
synthet
biolog
develop
new
vaccin
therapeut
improv
implement
efficaci
alreadi
market
one
major
complic
success
implement
vaccin
current
limit
time
vaccin
design
product
influenza
virus
requir
season
vaccin
determin
proper
formul
leav
littl
time
develop
implement
new
advanc
revers
genet
technolog
reduc
potenti
time
recoveri
product
month
week
instanc
dormitz
et
al
develop
improv
platform
approach
demonstr
current
revers
genet
technolog
feasibl
gener
recombin
influenza
viru
new
ha
na
sequenc
within
day
new
emerg
virus
continu
appear
pandem
continu
occur
rapid
approach
recov
adapt
virus
instrument
public
health
respons
develop
common
chimer
revers
genet
platform
rapid
clone
express
surfac
antigen
emerg
pathogen
help
increas
efficaci
time
deliveri
epidem
pandem
outbreak
one
key
limit
develop
effect
liveattenu
vaccin
genet
stabil
rna
virus
gener
exhibit
high
mutat
rate
due
decreas
fidel
rdrp
yet
recent
studi
shown
codonusag
bia
use
alter
translat
consequ
replic
virus
sever
group
shown
substitut
nonpref
codon
base
host
cell
codon
usag
bia
process
refer
codondeoptim
genom
polioviru
result
reduct
plaqu
area
viru
yield
chang
codon
rather
amino
acid
amount
viral
protein
may
modul
without
impair
function
importantli
potenti
revers
greatli
limit
due
sheer
number
codon
chang
introduc
code
sequenc
approach
repres
promis
new
avenu
develop
attenu
genet
stabl
vaccin
platform
despit
presenc
revers
genet
system
mani
human
pathogen
result
success
vaccin
platform
advanc
biotechnolog
key
discoveri
led
novel
revers
genet
approach
may
employ
new
gener
vaccin
structur
vaccinolog
structurebas
antigen
design
becom
common
practic
optim
antigen
display
vaccin
mention
previous
rsv
remain
key
hurdl
reduc
viral
childhood
morbid
sinc
discoveri
implement
palivizumab
current
licens
prophalyt
inhibitori
measur
rsv
infect
consider
energi
devot
evalu
antigen
site
rsv
fusion
f
protein
optim
f
express
construct
higher
immunogen
current
structur
vaccinolog
effort
evalu
prefus
postfus
antigen
form
rsv
f
protein
led
induct
identif
potent
neutral
antibodi
higher
neutral
potenc
palivizumab
avail
new
structur
sequenc
made
predict
structur
model
structurebas
antigen
design
viabl
option
renew
effort
design
vaccin
current
vaccin
exist
advanc
biotechnolog
shape
field
virolog
much
field
scienc
capac
engin
revers
genet
platform
studi
manipul
rna
viru
genom
revolution
field
vaccin
design
describ
rna
viru
revers
genet
system
past
current
effort
develop
vaccin
provid
immun
sever
human
rna
viru
pathogen
incorpor
new
advanc
revers
genet
technolog
adjuv
nonhuman
model
infect
surveil
continu
drive
develop
next
gener
vaccin
pathogen
alreadi
vaccin
strategi
well
current
ongo
chang
human
demograph
access
health
care
like
modifi
costbenefit
analys
provok
alloc
new
resourc
scientif
studi
develop
vaccin
despit
ongo
evolut
vaccin
design
implement
hallmark
effect
viral
vaccin
remain
high
efficaci
safeti
stabil
